Lifeward Ltd.
LFWDLifeward Ltd. in brief
Lifeward Ltd. is a listed company in the Medical Devices industry, based in Israel. Its market value was $17 M on 29 October 2026, which makes it the 24,829th largest listed company in the world and the 257th largest in Israel on this site. In the year to December 2025 it had sales of $22 M and a net loss of $20 M. It employs about 81 people. Its largest product and service lines by sales in 2025 were Service and warranty (14%) and Lease Of Products (8%). By market, the largest shares of its 2025 sales came from USA (60%), Germany (18%) and Europe (13%). Its shares trade under the symbol LFWD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lifeward Ltd.
We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury. These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community. In March 2023, we received clearance of our premarket notification (“510(k)”) from the U.S. Food and Drug Administration for the ReWalk Personal Exoskeleton with stair and curb functionality, which adds usage on stairs and curbs to the indication for use for the device in the U.S. The clearance permits U.S. customers to participate in more walking activities in real-world environments in their daily lives where stairs or curbs may have previously limited them when using the exoskeleton for its intended, FDA-indicated uses. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years consisting of over 18,000 stair steps, were collected to demonstrate the safety and efficacy of this feature and support the FDA submission. In March 2025, we received 510(k) clearance from the U.S. Food and Drug Administration for the ReWalk 7 Personal Exoskeleton device, a next-generation ReWalk model.
Lifeward Ltd. timeline
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- ✎Renamed ReWalk Robotics Ltd.Formerly Argo Medical Technologies Ltd..
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 💰Record revenue of $26 millionFY2024, the highest of the 8 years on record.
- ✎Renamed Lifeward Ltd.Formerly ReWalk Robotics Ltd..
Events of Lifeward Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #337 (Jan 2020) · #314 (Jan 2021) · #337 (Jan 2022) · #307 (Dec 2022) · #348 (Jul 2023) · #310 (Jan 2024) · #256 (Oct 2026) · #257 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.8×
- Price / book
- 2.0×
- Free cash flow yield
- -100.6%
- Net margin (TTM)
- -141.3%
- Operating margin
- -89.3%
- Return on equity
- -366.6%
- Liabilities / assets
- 63.3%
- Net debt
- $-15M
- Revenue growth
- -14.1%
- R&D / revenue
- 14.8%
- Revenue per employee
- $272 K
- Profit per employee
- $-246 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $22M | -14.1% | $-20M | $-20M | -90.4% |
| Dec 2024 | $26M | +85.3% | $-29M | $-29M | -112.8% |
| Dec 2023 | $14M | +151.4% | $-24M | $-22M | -159.8% |
| Dec 2022 | $6M | -7.7% | $-19M | $-20M | -355.2% |
| Dec 2021 | $6M | +36.0% | $-13M | $-13M | -213.4% |
| Dec 2020 | $4M | -9.9% | $-12M | $-13M | -295.7% |
| Dec 2019 | $5M | -25.5% | $-14M | $-16M | -319.3% |
| Dec 2018 | $7M | — | $-19M | $-22M | -331.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-17M | $0M | $-17M | $-17.16 | — |
| Dec 2024 | $-22M | $0M | $-22M | $-39.96 | — |
| Dec 2023 | $-21M | $0M | $-21M | $-31.13 | — |
| Dec 2022 | $-18M | $0M | $-18M | $-2.20 | — |
| Dec 2021 | $-11M | $0M | $-12M | $-0.27 | — |
| Dec 2020 | $-13M | $0M | $-13M | $-0.82 | — |
| Dec 2019 | $-15M | $0M | $-15M | $-2.70 | — |
| Dec 2018 | $-15M | $0M | $-15M | $-14.72 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $5M (-12.4% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 5, 20268-KCurrent reportShareholder vote
- Oct 27, 20268-KCurrent reportDirectors or officers changed
- Oct 8, 20268-KCurrent reportDirectors or officers changed
- Oct 1, 20268-KCurrent reportDirectors or officers changed
- Sep 25, 2026DEF 14AProxy statement
- Sep 15, 20268-KCurrent report
- Sep 8, 20268-KCurrent reportRegulation FD disclosure
- Aug 31, 20268-KCurrent reportDirectors or officers changed
- Aug 20, 20268-KCurrent reportDirectors or officers changed
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations · Directors or officers changed
- Jul 7, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
Official filings of Lifeward Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $22 M
- Operating income
- $-20 M
- Net income
- $-20 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $23 M
- Total liabilities
- $14 M
- Total equity
- $8 M
As of December-2025
Top 11 institutional investors in Lifeward Ltd.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies LLC | 10,727 | -600 (-5.30%) | 0.38% | $0 M | Nov 12, 2026 |
| 2 | Tower Research Capital LLC (TRC) | 3,040 | New | 0.11% | $0 M | Nov 16, 2026 |
| 3 | UBS Group AG | 1,952 | -200 (-9.29%) | 0.07% | $0 M | Nov 10, 2026 |
| 4 | Citigroup Inc | 518 | New | 0.02% | $0 M | Nov 4, 2026 |
| 5 | Morgan Stanley | 334 | +60 (+21.90%) | 0.01% | $0 M | Nov 13, 2026 |
| 6 | Osaic Holdings, Inc. | 226 | +119 (+111.21%) | 0.01% | $0 M | Nov 12, 2026 |
| 7 | SBI Securities Co., Ltd. | 196 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 8 | Royal Bank Of Canada | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 9 | National Bank Of Canada /fi/ | 11 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 10 | Caitong International Asset Management Co., Ltd | 7 | +3 (+75.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 11 | Kiker Wealth Management, LLC | 5 | New | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Lifeward Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 804 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 216 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 97 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lifeward Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Avraham GabayDirector | Grant or award | +13,643 | — | — | 13,643 | Form 4 |
| filed | Haggai ZamirDirector | Grant or award | +6,711 | — | — | 6,711 | Form 4 |
| filed | Yonason GreenwaldDirector | Grant or award | +6,711 | — | — | 6,711 | Form 4 |
| filed | Keith Dale RoseChief Medical Officer | Grant or award | +15,000 | — | — | 17,083 | Form 4 |
| filed | William Mark SigsbeeDirector | Grant or award | +11,485 | — | — | 11,485 | Form 4 |
| filed | Moshe H. RozenbaumDirector | Grant or award | +11,485 | — | — | 11,485 | Form 4 |
| filed | Yehuda ReznickDirector | Grant or award | +7,657 | — | — | 7,657 | Form 4 |
| filed | Nadav KidronDirector | Grant or award | +7,657 | — | — | 7,657 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lifeward Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 18-for-1 split in the period to ; 1-for-18 reverse split
Trading halts
- 2026-10-01 13:38 UTC, code LUDP, resumed 13:43 UTC
- 2026-02-24 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-01-13 12:55 UTC, code T3, resumed 13:30 UTC
- 2025-03-13 13:32 UTC, code LUDP, resumed 13:37 UTC
Fails to deliver
- : 35 shares at $5.90
- : 110 shares at $6.02
- : 110 shares at $5.93
- : 641 shares at $5.91
- : 726 shares at $6.17
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lifeward Ltd. scorecard#
Passes 6 of the 20 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.0×Price to book 2.0× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-100.6%Free cash flow is -100.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✗Revenue grew in the newest year-14.2%Revenue down 14.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years58.7%58.7% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median58.7%58.7% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-17.16 vs -39.96Diluted EPS -17.16 in fiscal 2025 against -39.96 the year before (report's currency).
- ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$13 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-89.3%-89.3% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-146.1%-146.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-89.3%-89.3% in fiscal 2025 against -346.6% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.31 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-18.39Z-score -18.39 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year60.4%Diluted shares up 60.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Lifeward Ltd.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -89.3% | -8.2% | |
| Net margin | -90.4% | -10.4% | |
| Return on equity | -146.1% | -16.8% | |
| Revenue growth, 3 years a year | 58.7% | 10.8% | |
| Revenue growth | -14.2% | 10.4% | |
| Free cash flow margin | -76.5% | -1.9% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 14.2% against the year before.
- Net loss of $20 million, the 14th loss-making year in a row.
- Free cash flow was negative: -$17 million.
- The share count rose 60.4% in the year.
Lifeward Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 22−14.1%100% | 26+85.2%100% | 14+151%100% | 5.5−7.6%100% | 6.0+35.8%100% | 4.4−9.9%100% | 4.9−25.5%100% | 6.5−15.6%100% | 7.8+32.1%100% | 5.9—100% | |
| Cost of revenue | 14−22.0%61.8% | 17+85.6%68.0% | 9.4+161%67.9% | 3.6+17.7%65.4% | 3.1+39.0%51.3% | 2.2+2.7%50.2% | 2.1−42.3%44.1% | 3.7−20.0%56.8% | 4.7−9.4%60.0% | 5.1—87.5% | |
| Gross profit | 8.4+2.6%38.2% | 8.2+84.5%32.0% | 4.5+134%32.1% | 1.9−34.4%34.6% | 2.9+32.6%48.7% | 2.2−19.7%49.8% | 2.7−3.5%55.9% | 2.8−8.9%43.2% | 3.1+321%40.0% | 0.7—12.5% | |
| Research and development | 3.2−29.8%14.7% | 4.6+11.5%18.0% | 4.1+2.9%29.9% | 4.0+37.2%73.1% | 2.9−15.0%49.3% | 3.5−35.3%78.7% | 5.3−27.2%110% | 7.3+21.6%112% | 6.0−33.1%77.9% | 9.0—154% | |
| Selling and marketing | 14−22.7%63.0% | 18+28.9%69.9% | 14+41.5%100% | 9.8+40.7%179% | 7.0+21.5%117% | 5.8−6.7%131% | 6.2−21.9%127% | 7.9−30.5%121% | 11−18.6%147% | 14—238% | |
| General and administrative | 8.2+57.7%37.2% | 5.2−48.0%20.2% | 10.0+40.1%72.1% | 7.1+26.8%129% | 5.6+13.0%94.3% | 5.0−5.3%113% | 5.3−22.6%108% | 6.8−11.7%104% | 7.7−6.1%99.2% | 8.2—140% | |
| Operating expenses | 28−25.2%128% | 38+33.8%146% | 28+33.6%203% | 21+35.0%381% | 16+9.6%261% | 14−15.4%323% | 17−23.9%344% | 22−12.2%337% | 25−19.5%324% | 31—531% | |
| Operating income | −20—−89.3% | −29—−114% | −24—−170% | −19—−347% | −13—−212% | −12—−273% | −14—−288% | −19—−294% | −22—−284% | −30—−519% | |
| Interest expense and finance costs | — | — | — | — | 0−100%0.0% | 0.9−39.5%20.6% | 1.5r1,500—30.8% | — | 2.5+24.0%31.6% | 2.0—33.7% | |
| Net interest income | −0.3−149%−1.4% | 0.6r0−52.5%2.5% | 1.4r0.0—9.8% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Income before tax | −20—−90.6% | −29—−113% | −22—−160% | −19—−347% | −13—−212% | −13—−294% | −16—−319% | −22—−331% | −25—−317% | −33—−554% | |
| Income tax | −0.1−228%−0.2% | 0.0—0.2% | −0.0−103%−0.1% | 0.5+397%8.5% | 0.1+84.3%1.6% | 0.1+629%1.2% | 0.0—0.1% | −0.0−104%−0.1% | 0.1+3867%1.5% | 0.0—0.1% | |
| Net income including minority interests | 20—90.3% | — | — | −20—−355% | −13—−213% | −13—−295% | −16—−319% | −22—−331% | −25—−319% | −33—−554% | |
| Net income attributable to shareholders | −20—−90.4% | −29—−113% | −22—−160% | −20—−355% | −13—−213% | −13—−295% | −16—−319% | −22—−331% | −25—−319% | −33—−554% | |
| Earnings per share, basic | -17.16—— | -39.96r-3.33—— | -31.13r-0.37—— | -2.20r-0.31—— | -0.27—— | -0.82—— | -2.70—— | -14.72r-0.59—— | -30.57r-1.22—— | -2.47—— | |
| Earnings per share, diluted | -17.16—— | -39.96r-3.33—— | -31.13r-0.37—— | -2.20r-0.31—— | -0.27—— | -0.82—— | -2.70—— | -14.72r-0.59—— | -30.57r-1.22—— | -2.47—— | |
| Shares, weighted average (basic) | 1.2+60.2%— | 0.7r8.7+1.9%— | 0.7r60−92.0%— | 8.9r62−81.4%— | 48+204%— | 16—— | — | — | — | — | |
| Shares, weighted average (diluted) | 1.2+60.2%— | 0.7r8.7+1.9%— | 0.7r60−92.0%— | 8.9r62−81.4%— | 48+204%— | 16+174%— | 5.8+291%— | 1.5r37+82.1%— | 0.8r20−93.9%— | 13—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2.2−67.8%9.5% | 6.7−76.0%22.1% | 28−58.6%44.4% | 68−23.1%91.5% | 88+334%93.2% | 20+25.2%72.5% | 16+70.3%66.7% | 9.5−34.5%63.8% | 15−38.5%63.7% | 24—74.5% | |
| Receivables | 6.1+2.2%26.8% | 6.0+92.4%19.7% | 3.1+201%4.9% | 1.0+77.1%1.4% | 0.6−14.5%0.6% | 0.7−13.9%2.4% | 0.8+4.7%3.3% | 0.8−31.3%5.1% | 1.1−12.0%4.8% | 1.3—3.9% | |
| Inventory | 5.7−14.7%25.0% | 6.7+18.9%22.1% | 5.7+93.0%8.9% | 2.9−2.0%3.9% | 3.0−15.6%3.2% | 3.5+13.4%12.6% | 3.1+39.4%12.8% | 2.2−38.5%15.0% | 3.6+11.6%15.9% | 3.3—10.3% | |
| Other current assets | 0.4+36.0%1.7% | 0.3r0.3−61.3%0.9% | 0.7r0.7+391%1.2% | 0.2r0.2+141%0.2% | 0.1r0.1+90.9%0.1% | 0.0r0.0−79.9%0.1% | 0.2r0.2−76.3%0.7% | 0.7+51.3%4.6% | 0.5r0.5−31.7%2.0% | 0.7r0.7—2.1% | |
| Current assets | 16−25.8%69.0% | 21−45.7%69.8% | 39−45.9%62.1% | 73−21.6%97.7% | 93+266%97.6% | 25+19.8%90.0% | 21+59.2%86.5% | 13−36.8%88.5% | 21−28.6%91.6% | 29r29—92.4% | |
| Property, plant and equipment | 0.6−32.5%2.6% | 0.9−31.3%2.8% | 1.3+544%2.0% | 0.2−31.0%0.3% | 0.3−35.0%0.3% | 0.4−12.8%1.6% | 0.5−20.0%2.1% | 0.6−25.5%4.2% | 0.8−33.2%3.7% | 1.3—4.0% | |
| Right-of-use (leased) assets | 1.5+182%6.7% | 0.5−70.6%1.8% | 1.9+123%2.9% | 0.8−5.1%1.1% | 0.9−34.7%0.9% | 1.3−22.3%4.8% | 1.7—7.1% | — | — | — | |
| Goodwill | 4.8−36.9%20.8% | 7.50.0%24.7% | 7.5—11.9% | 0—0.0% | — | — | — | — | — | — | |
| Other intangible assets | — | 0−100%0.0% | 13—19.8% | — | — | — | — | — | — | — | |
| Non-current assets | 7.1−22.8%31.0% | 9.2−61.6%30.2% | 24+1289%37.9% | 1.7−22.6%2.3% | 2.2−20.9%2.4% | 2.8−14.5%10.0% | 3.3+91.2%13.5% | 1.7−10.4%11.5% | 1.9−20.7%8.4% | 2.4r2.3—7.6% | |
| Total assets | 23−24.9%100% | 30−51.8%100% | 63−14.9%100% | 74−21.7%100% | 95+238%100% | 28+15.2%100% | 24+62.9%100% | 15−34.6%100% | 23−28.0%100% | 32—100% | |
| Accounts payable | 5.6+11.3%24.4% | 5.0−0.9%16.5% | 5.1+160%8.0% | 2.0+40.9%2.6% | 1.4−39.0%1.5% | 2.3−15.9%8.1% | 2.7+15.9%11.1% | 2.3+28.5%15.6% | 1.8−47.1%7.9% | 3.4—10.8% | |
| Debt due within a year | — | — | — | — | — | — | 5.4+216%22.3% | 1.7−73.3%11.5% | 6.4−14.1%28.2% | 7.5—23.6% | |
| Current liabilities | 12+17.7%52.6% | 10−13.3%33.5% | 12+147%18.7% | 4.8+18.4%6.4% | 4.0−13.5%4.3% | 4.7−54.1%16.6% | 10+88.9%41.7% | 5.4−44.7%36.0% | 9.7−21.5%42.5% | 12—39.0% | |
| Long-term debt | — | — | — | — | — | — | 1.5−78.1%6.3% | 7.0−21.8%46.6% | 8.9−15.3%39.0% | 11—33.1% | |
| Lease liabilities (non-current) | 1.2+5168%5.1% | 0.0−96.4%0.1% | 0.6+82.3%1.0% | 0.3−20.3%0.4% | 0.4−54.7%0.4% | 0.9−29.8%3.3% | 1.3—5.4% | — | — | — | |
| Non-current liabilities | 2.5+73.6%10.7% | 1.4−71.1%4.6% | 4.9+279%7.7% | 1.3−3.0%1.7% | 1.3−18.2%1.4% | 1.6−52.5%5.8% | 3.4−55.2%14.0% | 7.6−19.0%51.0% | 9.4−15.1%41.2% | 11—35.0% | |
| Total liabilities | 14+24.5%63.3% | 12−30.2%38.2% | 17+175%26.4% | 6.1+13.1%8.2% | 5.4−14.7%5.7% | 6.3−53.7%22.4% | 14+4.4%55.8% | 13−32.0%87.0% | 19−18.5%83.8% | 24—74.0% | |
| Retained earnings | −285—−1243% | −265—−869% | −236—−373% | −214—−288% | −194—−205% | −181—−646% | −168—−691% | −153—−1022% | −131—−574% | −106—−335% | |
| Shareholders' equity | 8.4−55.4%36.7% | 19−59.5%61.8% | 47−31.8%73.6% | 68−23.7%91.8% | 89+311%94.3% | 22+102%77.6% | 11+454%44.2% | 1.9−47.5%13.0% | 3.7−55.1%16.2% | 8.3—26.0% | |
| Total liabilities and equity | 23−24.9%100% | 30−51.8%100% | 63−14.9%100% | 74−21.7%100% | 95+238%100% | 28+15.2%100% | 24+62.9%100% | 15−34.6%100% | 23−28.0%100% | 32—100% | |
| Shares outstanding | 1.5+108%— | 0.7r8.8−91.5%— | 8.6r60−85.7%— | 60−3.8%— | 62+147%— | 25+246%— | 7.3+160%— | 2.8r70−90.6%— | 30+83.6%— | 16—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0.6−7.8%8.3% | 0.7—11.9% | |
| Share-based compensation | 0.7−42.0%3.4% | 1.3−3.5%5.0% | 1.3+33.7%9.6% | 1.0+19.2%18.0% | 0.8+11.2%14.0% | 0.7−32.4%17.0% | 1.1−59.9%22.7% | 2.8−24.3%42.3% | 3.7+7.5%47.1% | 3.4—57.9% | |
| Cash from operating activities | −17—−76.4% | −22—−84.6% | −21—−149% | −18—−325% | −11—−192% | −13—−287% | −15—−304% | −15—−226% | −22r−22—−290% | −27r−28—−456% | |
| Capital expenditure | −0.0—−0.1% | 0—0.0% | −0.1—−0.6% | −0.0—−0.5% | −0.0—−0.8% | −0.1—−1.7% | −0.0—−0.5% | −0.0—−0.2% | −0.0—−0.3% | −0.5—−7.7% | |
| Acquisitions, net of cash acquired | 0—0.0% | 0—0.0% | −18—−130% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from investing activities | −0.0—−0.1% | 0—0.0% | −18—−131% | −0.0—−0.5% | −0.0—−0.8% | −0.1—−1.7% | −0.0—−0.5% | −0.0—−0.2% | −0.0—−0.3% | −0.4—−7.4% | |
| Debt issued | 1.4—6.5% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.4—8.9% | — | — | 0−100%0.0% | 20—341% | |
| Debt repaid | — | — | — | 0—0.0% | 0—0.0% | −7.0—−159% | −1.7—−35.3% | −3.9—−59.1% | −3.1—−40.0% | −0.9—−15.7% | |
| Shares issued | — | — | — | — | — | — | — | 1.1−87.7%17.4% | 9.3+127%120% | 4.1—69.8% | |
| Cash from financing activities | 12—55.4% | 0—0.0% | −1.0—−7.2% | −2.5−103%−45.4% | 80+375%1333% | 17−22.1%381% | 21+121%441% | 9.7−27.6%148% | 13−60.3%173% | 34—576% | |
| Exchange-rate effect on cash | — | 0.0−24.4%0.1% | 0.0—0.3% | −0.1—−1.4% | 0—0.0% | 0—0.0% | — | — | — | — | |
| Change in cash | −4.5—−20.6% | −22—−84.5% | −40—−287% | −20−130%−372% | 68+1574%1140% | 4.1—92.5% | — | — | −9.1−257%−118% | 5.8—99.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 21−14.1%100% | 5.4−12.4%100% | 6.6+15.7%100% | 3.9−22.1%100% | 5.1*−32.7%100% | 6.2+1.1%100% | 5.7−14.7%100% | 5.0−4.7%100% | 7.5*+9.6%100% | 6.1—100% | 6.7—100% | 5.3—100% | 6.9*—100% | |
| Cost of revenue | 14−5.8%68.5% | 3.9+13.0%72.6% | 3.9+21.8%59.1% | 2.6−11.4%65.8% | 4.0*−30.0%78.6% | 3.5−10.7%56.3% | 3.2−18.7%56.1% | 2.9−25.1%57.8% | 5.7*+28.4%75.6% | 3.9—63.8% | 4.0—58.9% | 3.9—73.6% | 4.4*—64.5% | |
| Gross profit | 6.6−27.9%31.5% | 1.5−45.1%27.4% | 2.7+7.9%40.9% | 1.3−36.8%34.2% | 1.1*−41.0%21.4% | 2.7+21.9%43.7% | 2.5−8.9%43.9% | 2.1+52.1%42.2% | 1.8*−24.5%24.4% | 2.2—36.2% | 2.8—41.1% | 1.4—26.4% | 2.4*—35.5% | |
| Research and development | 10+194%49.3% | 1.9+169%35.8% | 1.8+129%26.5% | 5.8+537%149% | 0.8*−25.5%16.6% | 0.7−27.8%11.6% | 0.8−36.3%13.4% | 0.9−28.9%18.2% | 1.1*−14.2%15.0% | 1.0—16.3% | 1.2—18.0% | 1.3—24.4% | 1.3*—19.1% | |
| Selling and marketing | 13−12.7%62.9% | 3.4+5.8%61.7% | 3.5−6.7%53.3% | 3.3−14.8%83.4% | 3.1*−29.5%60.7% | 3.2−23.8%51.1% | 3.8−14.0%66.1% | 3.8−23.5%76.2% | 4.4*−9.7%58.0% | 4.2—67.8% | 4.4—65.6% | 5.0—94.9% | 4.8*—70.4% | |
| General and administrative | 8.6+11.7%40.8% | 2.2+10.6%39.9% | 1.6−9.4%23.8% | 2.6+15.5%65.4% | 2.3*+28.6%44.8% | 2.0+716%31.6% | 1.7+9.2%30.4% | 2.2+39.4%44.1% | 1.8*−26.7%23.5% | 0.2—3.9% | 1.6—23.7% | 1.6—30.1% | 2.4*—35.1% | |
| Operating expenses | 32−17.4%153% | 7.5+27.5%137% | 6.9−24.4%104% | 12+67.5%298% | 6.2*−63.6%122% | 5.8+8.4%94.4% | 9.1+26.0%159% | 7.0−11.7%139% | 17*+99.0%226% | 5.4—88.0% | 7.2—107% | 7.9—149% | 8.6*—125% | |
| Operating income | −26—−121% | −6.0—−110% | −4.2—−62.7% | −10—−264% | −5.1*—−101% | −3.1—−50.7% | −6.6—−115% | −4.9—−96.4% | −15*—−202% | −3.2—−51.8% | −4.4—−66.2% | −6.5—−123% | −6.1*—−89.1% | |
| Interest expense and finance costs | — | 0.4—7.5% | 7.1—107% | 0.4—10.6% | — | — | — | — | — | — | — | — | — | |
| Net interest income | — | — | — | — | −0.3*−149%−6.1% | 0*—0.0% | 0*—0.0% | 0−100%0.0% | 0.6r−0.0*−52.2%8.5% | −0.0*—−0.0% | −0.0*—−0.1% | 0.0—0.2% | 1.3r−0.0*—19.5% | |
| Income before tax | −33—−156% | −5.0—−92.9% | −12—−174% | −11—−275% | −5.4*—−107% | −3.2—−51.1% | −6.6—−115% | −4.8—−95.8% | −15*—−202% | −3.1—−49.9% | −4.3—−64.1% | −6.3—−119% | −5.7*—−83.0% | |
| Income tax | −0.0−333%−0.2% | 0.0+14.3%0.1% | 0.0—0.2% | 0.0−45.5%0.2% | −0.1*−2533%−1.4% | 0.0−75.9%0.1% | 0−100%0.0% | 0.0+83.3%0.2% | 0.0*—0.0% | 0.0—0.5% | 0.0—0.1% | 0.0—0.1% | −0.1*—−1.1% | |
| Net income attributable to shareholders | −33—−155% | −5.1—−93.1% | −12—−174% | −11—−275% | −5.3*—−105% | −3.2—−51.2% | −6.6—−115% | −4.8—−96.0% | −15*—−202% | −3.1—−50.3% | −4.3—−64.2% | −6.3—−119% | −5.6*—−81.9% | |
| Earnings per share, basic | — | -1.32—— | -4.12—— | -6.70—— | — | -2.37r-0.20—— | -7.01r-0.58—— | -5.53r-0.46—— | — | -0.35—— | -0.50—— | -0.73—— | — | |
| Earnings per share, diluted | — | -1.32—— | -4.12—— | -6.70—— | — | -2.37r-0.20—— | -7.01r-0.58—— | -5.53r-0.46—— | — | -0.35—— | -0.50—— | -0.73—— | — | |
| Shares, weighted average (basic) | 3.8+187%— | 3.8+187%— | 2.8+199%— | 1.6+84.4%— | — | 1.3r16−84.8%— | 0.9r11−89.1%— | 0.9r10−89.8%— | — | 8.8—— | 8.6—— | 8.6—— | — | |
| Shares, weighted average (diluted) | 3.8+187%— | 3.8+187%— | 2.8+199%— | 1.6+84.4%— | — | 1.3r16−84.8%— | 0.9r11−89.1%— | 0.9r10−89.8%— | — | 8.8—— | 8.6—— | 8.6—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.5—14.9% | 4.5+133%14.9% | 9.4+83.8%27.0% | 11+99.4%34.2% | 2.2−67.8%9.5% | 2.0−81.6%8.4% | 5.1−66.0%19.2% | 5.7−72.4%19.9% | 6.7−76.0%22.1% | 11—23.3% | 15—29.7% | 21—37.6% | 28—44.4% | |
| Receivables | 7.6—25.1% | 7.6+24.9%25.1% | 7.9+34.1%22.5% | 5.7+9.7%16.9% | 6.1+2.2%26.8% | 6.1+4.8%26.4% | 5.9+11.3%21.9% | 5.2+48.0%17.9% | 6.0+92.4%19.7% | 5.8—12.8% | 5.3—10.3% | 3.5—6.3% | 3.1—4.9% | |
| Inventory | 6.7—21.9% | 6.7−5.8%21.9% | 6.2−19.3%17.6% | 6.3−8.1%18.7% | 5.7−14.7%25.0% | 7.1−2.6%30.7% | 7.6+6.0%28.5% | 6.8+12.3%23.6% | 6.7+18.9%22.1% | 7.3—15.9% | 7.2—14.1% | 6.1—11.0% | 5.7—8.9% | |
| Other current assets | 2.3—7.4% | 2.3+17.8%7.4% | 2.0+5.8%5.7% | 1.8−4.4%5.5% | 0.4+36.0%1.7% | 1.9+5.6%8.3% | 1.9−8.6%7.0% | 1.9−22.6%6.7% | 0.3r0.3−61.3%0.9% | 1.8—4.0% | 2.0—4.0% | 2.5—4.5% | 0.7r0.7—1.2% | |
| Current assets | 22—71.1% | 22+25.1%71.1% | 26+25.3%74.1% | 26+29.0%76.5% | 16−25.8%69.0% | 17−32.3%74.9% | 21−30.1%77.3% | 20−39.6%68.8% | 21−45.7%69.8% | 26—56.0% | 30—58.1% | 33—59.4% | 39—62.1% | |
| Property, plant and equipment | 0.5—1.5% | 0.5−27.8%1.5% | 0.5−27.8%1.5% | 0.6−26.5%1.7% | 0.6−32.5%2.6% | 0.6−47.3%2.8% | 0.7−41.9%2.7% | 0.8−35.6%2.7% | 0.9−31.3%2.8% | 1.2—2.7% | 1.3—2.5% | 1.2—2.2% | 1.3—2.0% | |
| Right-of-use (leased) assets | 2.4—8.0% | 2.4+1005%8.0% | 2.5+599%7.1% | 1.5+226%4.5% | 1.5+182%6.7% | 0.2−76.6%1.0% | 0.4−71.8%1.3% | 0.5−70.7%1.6% | 0.5−70.6%1.8% | 0.9—2.1% | 1.3—2.5% | 1.6—2.8% | 1.9—2.9% | |
| Goodwill | 4.8—15.6% | 4.80.0%15.6% | 4.80.0%13.6% | 4.8−36.9%14.2% | 4.8−36.9%20.8% | 4.8−36.9%20.5% | 4.8−36.9%17.8% | 7.50.0%26.2% | 7.50.0%24.7% | 7.5—16.5% | 7.5—14.8% | 7.5—13.7% | 7.5—11.9% | |
| Other intangible assets | — | — | — | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 10—21.9% | 11—21.3% | 12—21.2% | 13—19.8% | |
| Non-current assets | 8.8—28.9% | 8.8+51.5%28.9% | 9.1+49.2%25.9% | 7.9−12.6%23.5% | 7.1−22.8%31.0% | 5.8−71.1%25.1% | 6.1−71.6%22.7% | 9.0−59.9%31.2% | 9.2−61.6%30.2% | 20—44.0% | 21—41.9% | 22—40.6% | 24—37.9% | |
| Total assets | 31—100% | 31+31.7%100% | 35+30.7%100% | 33+16.0%100% | 23−24.9%100% | 23−49.4%100% | 27−47.5%100% | 29−47.8%100% | 30−51.8%100% | 46—100% | 51—100% | 55—100% | 63—100% | |
| Accounts payable | 5.8—19.1% | 5.8+11.2%19.1% | 6.1+0.4%17.5% | 6.4+42.8%19.1% | 5.6+11.3%24.4% | 5.3+5.2%22.7% | 6.1+26.1%22.8% | 4.5+4.4%15.5% | 5.0−0.9%16.5% | 5.0—10.9% | 4.8—9.5% | 4.3—7.7% | 5.1—8.0% | |
| Current liabilities | 11—35.6% | 11+19.9%35.6% | 11+7.7%31.9% | 11+17.2%31.8% | 12+17.7%52.6% | 9.1−6.3%39.1% | 10+3.9%38.7% | 9.1−10.1%31.5% | 10−13.3%33.5% | 9.7—21.1% | 10.0—19.6% | 10—18.3% | 12—18.7% | |
| Lease liabilities (non-current) | 1.7—5.6% | 1.7+1845%5.6% | 1.8+2195%5.2% | 1.1+2219%3.3% | 1.2+5168%5.1% | 0.1+95.6%0.4% | 0.1−35.8%0.3% | 0.0−86.4%0.2% | 0.0−96.4%0.1% | 0.0—0.1% | 0.1—0.2% | 0.4—0.6% | 0.6—1.0% | |
| Non-current liabilities | 12—40.6% | 12+811%40.6% | 12+789%33.2% | 16+1187%49.4% | 2.5+73.6%10.7% | 1.4−38.7%5.9% | 1.3−69.8%4.9% | 1.3−71.6%4.4% | 1.4−71.1%4.6% | 2.2—4.9% | 4.3—8.5% | 4.5—8.2% | 4.9—7.7% | |
| Total liabilities | 23—76.2% | 23+123%76.2% | 23+95.3%65.1% | 27+162%81.2% | 14+24.5%63.3% | 10−12.3%44.9% | 12−18.4%43.6% | 10−29.1%35.9% | 12−30.2%38.2% | 12—25.9% | 14—28.0% | 15—26.4% | 17—26.4% | |
| Retained earnings | −312—−1023% | −312—−1023% | −307—−877% | −296—−884% | −285—−1243% | −279—−1206% | −276—−1032% | −270—−936% | −265—−869% | −250—−545% | −246—−483% | −242—−439% | −236—−373% | |
| Shareholders' equity | 7.3—23.8% | 7.3−43.0%23.8% | 12−19.2%34.9% | 6.3−65.9%18.8% | 8.4−55.4%36.7% | 13−62.4%55.1% | 15−58.8%56.4% | 18−54.6%64.1% | 19−59.5%61.8% | 34—74.1% | 37—72.0% | 41—73.6% | 47—73.6% | |
| Total liabilities and equity | 31—100% | 31+31.7%100% | 35+30.7%100% | 33+16.0%100% | 23−24.9%100% | 23−49.4%100% | 27−47.5%100% | 29−47.8%100% | 30−51.8%100% | 46—100% | 51—100% | 55—100% | 63—100% | |
| Shares outstanding | 2.8—— | 2.8−83.2%— | 2.8−81.9%— | 2.8−73.9%— | 1.5+108%— | 17+91.5%— | 16+81.4%— | 11+23.6%— | 0.7r8.8−91.5%— | 8.8—— | 8.6—— | 8.6—— | 8.6r60—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.7−12.5%3.4% | 0.1*−40.8%1.9% | 0.3*+44.0%4.0% | 0.2−19.5%4.5% | 0.2*−28.6%3.3% | 0.2*−40.0%2.8% | 0.2*−51.6%3.2% | 0.2−42.3%4.4% | 0.2*−37.3%3.1% | 0.3*—4.7% | 0.4*—5.6% | 0.4—7.2% | 0.4*—5.4% | |
| Cash from operating activities | −20—−93.2% | −6.4*—−118% | −6.0*—−90.7% | −3.7—−93.7% | −3.6*—−70.0% | −3.8*—−62.0% | −3.9*—−68.8% | −5.5—−109% | −4.0*—−52.6% | −4.5*—−72.8% | −5.6*—−83.7% | −7.7—−145% | −4.5*—−65.1% | |
| Capital expenditure | −0.0—−0.1% | 0*—0.0% | −0.0*—−0.1% | 0—0.0% | −0.0*—−0.2% | 0*—0.0% | 0*—0.0% | −0.0—−0.1% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.1*—−1.1% | |
| Acquisitions, net of cash acquired | — | — | 0*—0.0% | −6.5—−166% | — | — | 0*—0.0% | 0—0.0% | 0*—0.0% | — | — | — | 0*—0.0% | |
| Cash from investing activities | −0.0—−0.2% | −6.5*—−120% | −0.0*—−0.4% | 6.5—166% | −0.0*—−0.2% | 0*—0.0% | 0*—0.0% | −0.0—−0.1% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.1*—−1.1% | |
| Cash from financing activities | 22+164%106% | 8.0*+1138%147% | 4.1*+23.4%61.6% | 6.4+43.6%164% | 3.8*—74.4% | 0.6*—10.4% | 3.3*—57.8% | 4.5—88.8% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | 0.0—0.1% | 0.1*−8.7%0.8% | −0.0*—−0.2% | 0*—0.0% | −0.0—−0.3% | 0.1*—1.0% | |
| Change in cash | 2.6—12.4% | −4.9*—−90.4% | −1.9*—−29.3% | 9.3—236% | 0.2*—4.3% | −3.2*—−51.1% | −0.6*—−9.9% | −1.0—−20.3% | −3.9*—−51.8% | −4.5*—−73.0% | −5.6*—−83.7% | −7.7—−146% | −4.5*—−65.3% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Lifeward Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Sale of product(total)$17 M78%-14%
- Service and warranty$3 M14%-3.1%
- Lease Of Products$2 M8.1%-30%
Countries and regions
- 🇺🇸 USA$13 M60%-8.2%
- 🇩🇪 Germany$4 M18%-9.3%
- Europe$3 M13%-43%
- Rest Of World$1 M6.4%+63%
- Asia Pacific$0 M2.1%-44%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Lifeward Ltd. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters | — |
| 🇺🇸 USA | 1 office | $13 M60% |
| 🇩🇪 Germany | $4 M18% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Lifeward Ltd.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $835 K | $621 K | — | $11 |
| 2024Chief executive | $473 K | $279 K | — | $33 |
| 2023Chief executive | $889 K | $861 K | — | $63 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Lifeward Ltd.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 13 · Material agreement 4 · New debt 4 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officersUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
How Lifeward Ltd. compares in Medical Devices
- Market cap$17 M · higher than 10% of 142
- Revenue$22 M · higher than 21% of 155
- Net margin-141.3% · higher than 13% of 144
- Revenue growth-14.2% · higher than 7% of 104
- Price / sales0.8× · lower than 91% of 96
- Price / book2.0× · lower than 62% of 99
- FCF yield-100.6% · higher than 3% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lifeward Ltd.🇮🇱 | $17 M | — | -141.3% | -14.2% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lifeward Ltd.? Verify and update this profile — free
Show Lifeward Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.